Biocure Technology (CNSX:CURE) shares were down 1.8% during trading on Thursday . The stock traded as low as $0.27 and last traded at $0.27, approximately 2,000 shares changed hands during trading. The stock had previously closed at $0.28.
The company’s fifty day moving average price is $0.29.
Biocure Technology Company Profile (CNSX:CURE)
Biocure Technology Inc develops and commercializes biosimilar pharmaceutical products in South Korea. The company is developing Interferon Beta 1b for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions.
Recommended Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Biocure Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocure Technology and related companies with MarketBeat.com's FREE daily email newsletter.